April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Uveitis With Conjunctival and Episcleral Granulomas Associated With Brimonidine Treatment
Author Affiliations & Notes
  • P. A. Labalette
    Ophthalmology,
    University of Lille-CHRU, Lille, France
  • N. Franquet
    Ophthalmology,
    University of Lille-CHRU, Lille, France
  • L. Nouvel
    Ophthalmology,
    University of Lille-CHRU, Lille, France
  • O. Kerdraon
    Pathology,
    University of Lille-CHRU, Lille, France
  • C.-A. Maurage
    Pathology,
    University of Lille-CHRU, Lille, France
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 3786. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      P. A. Labalette, N. Franquet, L. Nouvel, O. Kerdraon, C.-A. Maurage; Uveitis With Conjunctival and Episcleral Granulomas Associated With Brimonidine Treatment. Invest. Ophthalmol. Vis. Sci. 2010;51(13):3786.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : The spectrum of drug induced uveitis expands with introduction of newer active medications. Anterior granulomatous uveitis has been recently reported as a side effet of chronic topical use of brimonidine tartrate. In this study, we describe the clinical features of patients with brimonidine induced uveitis and ocular wall granulomas.

Methods: : Seven patients presented with uveitis and granulomatous ocular wall infiltration induced by brimonidine topical treatment were included. Medical history, ocular features, progress of events, pathological aspect, and clinical evolution were analyzed. For each case, the search of systemic sarcoidosis was performed including chest computed tomography and accessory salivary gland biopsy.

Results: : Two women and five men with a mean age of 67 years (varying from 50 to 83 year-old). All patients presented with glaucoma and two patients had a previous history of unilateral uveitis before treatment with brimonidine. All but two patients receiving unilateral treatment had bilateral disease. At the time of diagnosis, the mean duration of treatment with brimonidine was 18 months. Epithelioid granulomatous lesions infiltrated both conjunctiva and episclera. Remission was obtained after about six weeks of withdrawal. Underlying sarcoidosis was suspected in one case but withdrawal of brimonidine allowed resolution of inflammation.

Conclusions: : Brimonidine associated uveitis arises after sustained treatment. Ocular inflammation happens only in treated eyes of susceptible patients. Coexisting granulomatous anterior uveitis and ocular wall granulomas in patient receiving brimonidine eye drops should evoke a drug induced disease.Treatment withdrawal leads to resolution of added inflammation with return to the basal state.Associated granulomatous uveitis and ocular wall granulomas in patients receiving topical brimonidine tartrate should lead to stop the treatment to assess causality. As a precaution, brimonidine should be avoided in patients presenting granulomatous anterior uveitis.

Keywords: drug toxicity/drug effects • uveitis-clinical/animal model 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×